Skip to Main Content

Speaking Monday night to investors on a conference call, CytoDyn CEO Nader Pourhassan said the company had requested a “conditional” emergency use authorization from the Food and Drug Administration for an experimental Covid-19 antibody treatment, despite its failure in a late-stage clinical trial.

But a “conditional” EUA — as described by CytoDyn’s CEO — does not exist.


“If you look at the law there is no such thing. You can certainly say that,” an FDA official told STAT on Wednesday, in response to the claims made by CytoDyn. The official asked not to be identified because of rules barring the agency from discussing regulatory matters involving unapproved drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.